Table 1

Demographics and clinical features of overall cohort for patients with vs. without cancera
Characteristics Cancer subgroups
No cancer (n= 2,023) Total (N= 154) Breast (n= 65) Lung (n= 16) Haemato (n= 19) GI (n= 17) GU (n= 6) Gynae (n= 17) Skin (n= 6)
Sex
Female, n (%) 1,663 (82.2) 131 (85.1) 65 (100) 12 (75) 14 (73.7) 13 (76.5) 2 (33.3) 17 (100) 3 (50)
Male, n (%) 360 (17.8) 23 (14.9) NA 4 (25) 5 (26.3) 4 (23.5) 4 (66.7) NA 3 (50)
SSc/cancer onset
Median age (±SD) at SSc onset, years 45 (±14.1) 53 (±11.9) 53 (±11.1) 47 (±19.5) 51.5 (±9.4) 53 (±11.4) 59 (±18.4) 53 (±23.7) 59.5 (±19.1)
IQR = 35 to 55 IQR = 43 to 58 IQR = 44 to 58 IQR = 41 to 54 IQR = 44 to 56 IQR = 45 to 60 IQR39 to 68 IQR = 35 to 57 IQR = 46 to 63
Cancer prior to SSc onset (median ± SD), months No cancer 39.5 (±81.6) 36 (±77.3) NA 109 (±88.2) 8.5 (±27.7) 25 (±74.4) 141 (±104.8) NA
IQR = 12 to 125 IQR = 11 to 114 IQR = 29 to 190 IQR = 1 to 48 IQR = 4 IQR = 25 to 243
Cancer after SSc onset, (median ± SD), months No cancer 119 (±95.3) 108 (±108.5) 125 (±93.8) 101 (±73.4) 168 (±90.6) 116.5 (±79.9) 137 (±91.9) 62 (±55.5)
IQR = 41 to 185 IQR = 25 to 209 IQR = 71 to 200 IQR = 20 to 161 IQR = 119 to 233 IQR = 60 IQR = 20 to 194 IQR = 23 to 125
SSc subsets
dcSSc, n (%) 657 (32.5) 53 (34.4) 22 (33.8) 5 (31.3) 8 (42.1) 4 (23.5) 2 (33.3) 4 (23.5) 3 (50)
lcSSc, n (%) 1,260 (62.3) 98 (63.6) 42 (64.6) 11 (68.8) 11 (57.9) 12 (70.6) 3 (50) 13 (76.5) 3 (50)
Missing cases, n (%) 106 (5.2) 3 (1.9) 1 (1.5) 0 (0) 0 (0) 1 (5.9) 1 (16.7) 0 (0) 0 (0)
SSc autoantibody status
ACA, n (%) 550 (27.2) 40 (26) 17 (26.2) 2 (12.5) 4 (21.1) 8 (47.1) 1 (16.7) 6 (35.3) 1 (16.7)
Scl to 70, n (%) 416 (20.6) 28 (18.2) 10 (15.4) 5 (31.3) 5 (26.3) 1 (5.9) 1 (16.7) 4 (23.5) 1 (16.7)
RNAP, n (%) 247 (12.2) 41 (26.6) 19 (29.2) 4 (25) 5 (26.3) 3 (17.6) 2 (33.3) 3 (17.6) 3 (50)
Others, n (%) 515 (25.4) 31 (20) 13 (19.9) 3 (18.9) 4 (21) 3 (17.6) 1 (16.7) 4 (23.6) 1 (16.7)
ANA-negative, n (%) 75 (3.7) 9 (5.8) 4 (6.2) 0 (0) 1 (5.3) 2 (11.8) 1 (16.7) 0 (0) 0 (0)
Missing cases, n (%) 220 (10.9) 5 (3.2) 2 (3.1) 2 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Organ involvementb
Lung fibrosis, n (%) NA 52 (33.8) 24 (36.9) 8 (50) 6 (31.6) 4 (23.5) 3 (33.3) 2 (11.8) 2 (33.3)
PAH, n (%) NA 27 (17.5) 15 (23.1) 1 (6.3) 3 (15.8) 3 (17.6) 0 (0) 2 (11.8) 1 (16.7)
GI, n (%) NA 85 (55.2) 35 (53.8) 9 (56.3) 12 (63.2) 9 (52.9) 1 (16.7) 10 (58.8) 3 (50)
SRC, n (%) NA 16 (10.4) 4 (6.2) 1 (6.3) 2 (10.5) 4 (23.5) 1 (16.7) 2 (11.8) 0 (0)

aACA, Anticentromere antibody; ANA, Antinuclear antibody; dcSSc, Diffuse cutaneous systemic sclerosis; GI, Gastrointestinal; GU, Genitourinary; Gynae, Gynaecological; Haemato, Haematological; IQR, Interquartile range; lcSSc, Limited cutaneous systemic sclerosis; NA, Not applicable; PAH, Pulmonary arterial hypertension; RNAP, RNA polymerase III; SRC, Scleroderma renal crisis; SSc, Systemic sclerosis. Cohort sample populations comprised 154 SSc patients with cancer and 2,023 SSc patients without cancer. bExtent and pattern of organ involvement is defined in the Methods section.

Moinzadeh et al.

Moinzadeh et al. Arthritis Research & Therapy 2014 16:R53   doi:10.1186/ar4486

Open Data